bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Psoriasis
Suicide
 Resources from HONselect
FDA Approves Injectable Psoriasis Drug for Tough Cases
But Siliq poses increased risk of suicidal behavior, agency warns

By Robert Preidt

THURSDAY, Feb. 16, 2017 (HealthDay News) -- A new drug to treat tough cases of the skin condition psoriasis has won approval from the U.S. Food and Drug Administration.

Valeant Pharmaceuticals' injectable drug Siliq (brodalumab) was approved for adults with moderate-to-severe psoriasis that isn't responding to other recommended treatments. However, the drug carries a warning about increased risk for suicidal behavior.

Psoriasis is characterized by raised patches of red skin and flaking. The condition usually begins between ages 15 and 35 and is thought to be an autoimmune disorder, meaning the body mistakenly attacks healthy cells.

"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today's approval provides patients with another treatment option for their psoriasis," said the FDA's Dr. Julie Beitz.

Beitz is director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research.

The drug is intended for patients who are candidates for systemic therapy -- treatment with pills or injectable drugs that travel through the bloodstream -- or phototherapy (ultraviolet light treatment), and have failed to respond or stopped responding to past therapies, the FDA said.

The drug works by inhibiting the inflammatory response that contributes to development of plaque psoriasis, the most common form of the skin disease, the FDA said.

Siliq's approval was based on three clinical trials that included more than 4,300 patients. Compared to those who took a placebo, more of those participants who took the drug had skin that was clear or almost clear, the agency said.

However, the drug carries a "boxed warning" about the risk of suicidal thoughts and attempts and it's only available through a suicide risk evaluation program, the FDA said.

Among patients who took Siliq, those with a history of suicide attempts or depression had greater risk of suicidal thoughts and attempts compared to others, according to trial results. However, a direct cause-and-effect relationship wasn't established.

"Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment," Beitz said in an agency news release.

Because Siliq affects the immune system, patients also may have a greater risk of getting an infection, or an allergic or autoimmune condition, the FDA said.

The most common side effects reported in the trials included joint and muscle pain, headache, fatigue, nausea or diarrhea, low white blood cell count and fungal infections.

More information

The American Academy of Family Physicians has more on psoriasis.

SOURCE: U.S. Food and Drug Administration, news release, Feb. 15, 2017

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=719738

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Psoriasis
Risk
Therapeutics
Evaluation Studies
Infection
Drug Evaluation
Behavior
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact